ArticleCancer immunology, immunotherapy : CII2025

Ki-67 expression stratifies PD-L1-high NSCLC for immune checkpoint inhibitor plus chemotherapy: a real-world biomarker validation.

Ning Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.